Interferon Beta Drugs Slow the Progression of Relapsing Multiple Sclerosis and Reduce the Frequency of Clinical Symptoms
Interferon
beta drugs are a part of the normal standard therapy for patients suffering
from multiple sclerosis. Interferon beta-1b slows the progression of relapsing
multiple sclerosis and reduces the frequency of clinical symptoms. However, as
a consequence of multiple sclerosis and especially when an immune deficiency
disorder is involved, the use of these drugs for treating multiple sclerosis victims
can sometimes prove to be inappropriate. Furthermore, it has also been used for
the therapy of hepatitis C in Japan previously but is currently not approved
for the therapeutic treatment of HCV in many countries.
Multiple
sclerosis patients usually respond very well to interferon
beta drugs. The drugs are administered in combination with other
medications and therapies such as phototherapy, cortisone, and biologic therapy
which can also have favorable results in some patients. Phototherapy uses
light-activated substances such as water, vegetables, and algae to suppress
MS-inflammatory cells. Biologic therapy uses living agents such as interferon
beta-1a or interferon gamma, xylene, or other systemic antigens which are then
delivered by means of skin creams, intravenous, intramuscular, and oral
vaccines.
Interferon
beta drugs may be given to people who have moderate to severe multiple
sclerosis, including people with both hemispheres of the cerebral disc. It is
critical for people with multiple sclerosis to follow the guidelines because
they provide a solid background for determining which treatment options are
appropriate. Multiple sclerosis is a debilitating disease that causes many
problems for patients and their families. Often people with this condition lose
the ability to live a normal life and can become depressed or anxious. Taking
these new guidelines into consideration may help improve the quality of life
for people with MS.
There
are several interferon beta drugs in the market today. Some of the most common
brands include Avonex (interferon beta 1a), Rebif (interferon beta 1a), Plegridy
(peginterferon beta 1a), Betaferon (interferon beta 1b), and Extavia
(interferon beta 1b). It is important that patients consult with their physicians
before using these medications in order to determine the proper dosage for each
patient. Patients with multiple sclerosis who are receiving treatment through
an interferon beta-drug regimen should only take the drug in accordance with
the doctor's orders.
Comments
Post a Comment